TTK Healthcare Limited has informed the Exchange about General Updates
TTKHLTCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Diversified peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
TTK Healthcare reported Q1 FY26 (quarter ended June 30, 2025) revenue from operations of Rs. 22,642.98 lakhs, up about 9% from Rs. 20,790.21 lakhs in Q1 FY25. Net profit after tax fell sharply to Rs. 1,299.94 lakhs from Rs. 3,157.51 lakhs in the same quarter last year, a drop of roughly 59%. The headline PAT decline is largely a comparison effect because Q1 FY25 included a one-time exceptional gain of Rs. 1,977.05 lakhs from the sale of leasehold land at Mahindra World City, Chennai. Excluding exceptional items, pre-tax profit still declined to Rs. 1,765.35 lakhs from Rs. 2,102.38 lakhs, indicating real margin pressure in core operations. Segment-wise, Consumer Products and Foods divisions saw sharp profit declines despite stable revenues, while Medical Devices posted solid profit growth. EPS for the quarter stood at Rs. 9.20 versus Rs. 22.35 in Q1 FY25. The statutory auditor (PKF Sridhar & Santhanam LLP) issued an unqualified limited review report with no qualifications.
The dramatic PAT drop looks alarming on the surface but is mostly distorted by last year's one-time land sale gain. Stripping that out, the business still showed ~16% pre-tax profit decline on 9% revenue growth, pointing to genuine margin compression that shareholders should monitor, especially in the Consumer Products and Foods segments.